FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 769 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Deaf Football Team Makes History, Heads To School’s First Finals Game... November 24, 2021 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... July 16, 2020 “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... July 2, 2021 Load more HOT NEWS ESMO Immuno-Oncology Virtual Congress 2020 Woman Who Lost Husband to Male Breast Cancer Goes on Road... Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... Study Improves the Quality of Biopsy Specimens for Cancer Research
